医疗器械开发商Advanced Bifurcation Systems完成对Svelte Medical Systems所有资产的收购-动脉网

Advanced Bifurcation Systems Inc. Acquires Svelte Medical Systems, Inc.

CISION 等信源发布 2026-04-27 20:59



可切换为仅中文







LIVERMORE, Calif.

加利福尼亚州利弗莫尔

，

April 27, 2026

2026年4月27日

/PRNewswire/ -- Advanced Bifurcation Systems Inc. ('ABS'), a leader in innovative solutions for bifurcation lesions in coronary angioplasty, today announced that it has recently acquired all assets of Svelte Medical Systems, Inc. ('Svelte').

/PRNewswire/ -- Advanced Bifurcation Systems Inc.（“ABS”），作为冠状动脉成形术中分叉病变创新解决方案的领导者，今日宣布其近期已收购Svelte Medical Systems, Inc.（“Svelte”）的所有资产。

The acquired portfolio includes Svelte's drug-eluting coronary stents, all intellectual property, and the related comprehensive set of US and international regulatory approvals and filings: U.S. Food and Drug Administration ('FDA') Premarket Approval ('PMA'); Europe (CE Mark); and Japan (PMDA).

收购的产品组合包括Svelte的药物洗脱冠状动脉支架、所有知识产权，以及相关的全套美国和国际监管批准和文件：美国食品药品监督管理局（“FDA”）的上市前批准（“PMA”）；欧洲（CE标志）；日本（PMDA）。

This acquisition places ABS in a small group of select global companies possessing an FDA-approved drug eluting coronary stent. Combined with ABS's innovative platform (for which ABS was awarded FDA's Breakthrough Device Designation), the acquisition will accelerate ABS's development pathway for its bifurcation-focused technology platform and materially strengthen ABS's presence in the global interventional cardiology market..

此次收购使ABS成为拥有FDA批准的药物洗脱冠状动脉支架的少数精选全球公司之一。结合ABS的创新平台（ABS因此平台荣获FDA的突破性设备认定），此次收购将加速ABS专注于分叉病变的技术平台的开发进程，并显著增强ABS在全球介入心脏病学市场的地位。

'As we advance our mission to transform the treatment of coronary bifurcation lesions, this acquisition will expand our commercial portfolio and represents a pivotal strategic milestone,' said Mehran Khorsandi, MD, Chairman and Chief Executive Officer of ABS. 'Our technology is designed to address the complexities of coronary bifurcation disease through a simplified, reproducible, and anatomy-preserving approach that overcomes limitations of current techniques.

“随着我们推进改变冠状动脉分叉病变治疗的使命，此次收购将扩大我们的商业产品组合，并代表着一个关键的战略里程碑，”ABS公司董事长兼首席执行官Mehran Khorsandi博士表示。“我们的技术旨在通过一种简化、可复制且保留解剖结构的方法来应对冠状动脉分叉疾病的复杂性，克服现有技术的局限性。”

It's devised to improve procedural efficiency and clinical outcomes, while reducing the need for repeat interventions and more invasive surgical procedures.' .

它旨在提高手术效率和临床效果，同时减少重复干预和更具侵入性的外科手术的需要。

For more information about Advanced Bifurcation Systems and its revolutionary approach to coronary artery bifurcation stenting, visit

有关高级分叉系统及其在冠状动脉分叉支架方面的革命性方法的更多信息，请访问

www.advancedbifurcation.com

。

Contacts:

联系人：

Advanced

高级设置

Bifurcation

分支

Systems,